Cardiotoxicity of de Gramont's regimen: Incidence, clinical characteristics and long-term follow-up


Creative Commons License

Meydan N., Kundak I., YAVUZŞEN T., Oztop I., Barutca S., Yilmaz U., ...More

JAPANESE JOURNAL OF CLINICAL ONCOLOGY, vol.35, no.5, pp.265-270, 2005 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35 Issue: 5
  • Publication Date: 2005
  • Doi Number: 10.1093/jjco/hyi071
  • Journal Name: JAPANESE JOURNAL OF CLINICAL ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.265-270
  • Keywords: 5-fluorouracil, cardiotoxicity, de Gramont's regimen, follow-up, leucovorin, HIGH-DOSE LEUCOVORIN, DIHYDROPYRIMIDINE DEHYDROGENASE, CONTINUOUS-INFUSION, 5-FLUOROURACIL CARDIOTOXICITY, CHEMOTHERAPY TREATMENT, RALTITREXED TOMUDEX, COLORECTAL-CANCER, CIRCADIAN-RHYTHM, FOLINIC ACID, RAT-LIVER
  • Dokuz Eylül University Affiliated: No

Abstract

Background: The incidence of 5-fluorouracil (5-FU)-related cardiotoxicity seems to be dosage and schedule dependent. It was reported as 1.6-3% with earlier bolus regimens whereas this increased up to 7.6-18% with prolonged (4-5 days) infusion regimens. Knowledge of the cardiotoxicity incidence in patients treated with the widely used de Gramont's regimen (2 days infusional 5-FU) and the long-term follow-up of affected patients is still limited.